
Aeterna Zentaris AEZS
Annual report 2024
added 02-07-2026
Aeterna Zentaris Total Non Current Liabilities 2011-2026 | AEZS
Annual Total Non Current Liabilities Aeterna Zentaris
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 19.1 M | 16.8 M | 17.5 M | 19.2 M | 21.2 M | - | 25.4 M | 34.9 M | 58.7 M | 62 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62 M | 16.8 M | 30.5 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 308.48 | -4.12 % | $ 40.4 B | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.51 | -0.58 % | $ 8.45 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
332 | $ 3.92 | 1.03 % | $ 334 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
158 M | $ 2.85 | -8.06 % | $ 160 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
2.21 M | $ 0.85 | 4.43 % | $ 4.64 M | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
Bristol-Myers Squibb Company
BMY
|
59.9 B | $ 59.86 | -0.12 % | $ 122 B | ||
|
BioNTech SE
BNTX
|
341 M | $ 105.76 | -3.31 % | $ 27.2 B | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 218.1 | -1.53 % | $ 5 B | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
2.29 M | $ 38.34 | -6.1 % | $ 3.96 B | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.38 | -3.5 % | $ 352 M | ||
|
CRISPR Therapeutics AG
CRSP
|
70.2 M | $ 48.93 | 1.26 % | $ 4.4 B | ||
|
Amneal Pharmaceuticals
AMRX
|
2.42 B | $ 14.63 | -0.48 % | $ 4.52 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B |